最新消息
News
HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline漢康生技攜手藥明生物，推進新一代雙/多功能融合蛋白平臺及多專案產品線開發
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.
致力於開發下一代免疫療法的全球臨床階段生物技術公司漢康生技與全球領先的CRDMO服務公司藥明生物共同宣佈，雙方簽署戰略合作協定，藥明生物將為漢康生技管線中多款新一代雙功能及多功能融合蛋白專案提供開發與生產服務。
1 月 26, 2026
Read more
HanchorBio Secures Japanese Patent for Engineered SIRPα-IgG4 Fusion Protein HCB101漢康生技創新 SIRPα/CD47 融合蛋白生物藥 HCB101 獲日本專利核准
HanchorBio Secures Japanese Patent for Engineered SIRPα […]
1 月 23, 2026
Read more
HanchorBio Reports High Objective Response Rate with HCB101 Combination in Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation漢康生技於2026 ASCO GI消化道腫瘤大會發表 HCB101 聯合標準治療在二線胃癌之臨床數據
HanchorBio Reports High Objective Response Rate with HC […]
1 月 09, 2026
Read more
HanchorBio to Present Encouraging Early Clinical Activity of HCB101 in Combination with Standard-of-Care Therapy for Second-Line Gastric Cancer at ASCO GI 2026漢康生技將於2026 ASCO消化道腫瘤大會發布 HCB101 聯合標準治療在二線胃癌中的早期臨床數據
HanchorBio to Present Encouraging Early Clinical Activi […]
1 月 05, 2026
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025漢康生技HCB101獲選2025年ESMO免疫腫瘤學大會口頭報告
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 12, 2025
Read more
【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 10, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果
HanchorBio Presents First-in-Human Data of HCB101 Monot […]
12 月 09, 2025
Read more
【Meeting Preview】HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting 漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據
HanchorBio Presents First-in-Human Phase 1 Data of HCB1 […]
12 月 03, 2025
Read more
漢康生技三靶點融合蛋白HCB301完成兩個劑量組安全性評估 全球臨床推進再跨一步
漢康生技（HanchorBio, KY-7827）宣布，其以自主 FBDB™ 多功能融合蛋白平台 開發的 三靶點創新藥 HCB301，已完成臨床一期前兩個劑量組安全性觀察，結果顯示耐受性良好，具臨床開發潛力。HCB301 兼具阻斷 SIRPα-CD47、PD-1/PD-L1 及 TGFβ 三大機制，能同時啟動先天與適應性免疫、克服腫瘤免疫抑制，為難治型癌症帶來新療法。該試驗（NCT06487624）正於中美兩地進行，台灣審查中，顯示漢康在免疫融合蛋白領域的全球開發邁出重要一步。
11 月 11, 2025
Read more
HanchorBio Presents Preclinical Data at the SITC 2025 on HCB301, a First-in-Class Tri-Specific Immunotherapy Targeting SIRPα-CD47, PD-1/PDL1, and TGFβ 漢康生技在SITC 2025公佈HCB301臨床前資料首創三特異性免疫療法靶向SIRPα-CD47、PD-1/PD-L1和TGFβ
Novel fusion protein shows potent macrophage activation […]
11 月 06, 2025
Read more